Topic Review
The Pharmacological Approaches in NTG Therapy
Normal tension glaucoma (NTG) is defined as a subtype of primary open-angle glaucoma (POAG) in which the intraocular pressure (IOP) values are constantly within the statistically normal range without treatment and represents approximately the 30–40% of all glaucomatous cases. NTG first recognized as a clinical entity by von Graefe in 1857, is a subtype of primary glaucoma characterized by open-angle and IOP values constantly within the statistically normal range without treatment.
  • 251
  • 01 Sep 2023
Topic Review
Tumor Microenvironment and Glioblastoma Cell Interplay
The invasive nature of glioblastoma is problematic in a radical surgery approach and can be responsible for tumor recurrence. In order to create new therapeutic strategies, it is imperative to have a better understanding of the mechanisms behind tumor growth and invasion. The continuous cross-talk between glioma stem cells (GSCs) and the tumor microenvironment (TME) contributes to disease progression, which renders research in this field difficult and challenging.
  • 217
  • 01 Sep 2023
Topic Review
Photon-Counting CT Technology
Photon-counting computed tomography (PCCT) is an emerging technology that can potentially transform clinical CT imaging. The improved diagnostic performance of PCCT over conventional CT in the diagnosis and characterization of cardiovascular diseases has been demonstrated in several phantom, animal, and even human studies. 
  • 437
  • 01 Sep 2023
Topic Review
For the Cure of Atopic Dermatitis
Patients with atopic dermatitis (AD) are seeking a permanent cure. This entry provides three working hypotheses and perspectives for the cure of AD by restoring immune homeostasis (immune tolerance state) through activation of regulatory T (Treg) cells as follows. (1) A decreased number or function of Treg cells is a critical event leading to the development and maintenance of AD. (2) Activation of Treg cells is an effective therapeutic approach for long-term clinical improvement of AD. (3) Many different immunomodulatory strategies activating Treg cells can provide a long-term treatment-free clinical remission (cure) of AD by induction of immune tolerance state. Currently available Treg cell-targeted immunomodulatory therapies for AD include allergen immunotherapy, microbiota, vitamin D, polyvalent human immunoglobulin G, and monoclonal antibodies to the surface antigens of T cell or antigen-presenting cell. 
  • 344
  • 01 Sep 2023
Topic Review
Pharmacological and Non-Pharmacological Treatments for Depression in PD
Depression represents one of the most common non-motor disorders in Parkinson’s disease (PD) and it has been related to worse life quality, higher levels of disability, and cognitive impairment, thereby majorly affecting not only the patients but also their caregivers. Available pharmacological therapeutic options for depression in PD mainly include selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, and tricyclic antidepressants; meanwhile, agents acting on dopaminergic pathways used for motor symptoms, such as levodopa, dopaminergic agonists, and monoamine oxidase B (MAO-B) inhibitors, may also provide beneficial antidepressant effects. There is a growing interest in non-pharmacological interventions, including cognitive behavioral therapy; physical exercise, including dance and mind–body exercises, such as yoga, tai chi, and qigong; acupuncture; therapeutic massage; music therapy; active therapy; repetitive transcranial magnetic stimulation (rTMS); and electroconvulsive therapy (ECT) for refractory cases.
  • 458
  • 01 Sep 2023
Topic Review
Neoadjuvant and Adjuvant Therapy for Gastric Cancer
Gastric cancer is a deadly disease with worldwide prevalence that is often diagnosed at late stages. About two-thirds of patients in Western countries will present with locally advanced gastric cancer (LAGC). When patients are diagnosed with LAGC, they frequently undergo surgery and perioperative chemotherapy. However, the most effective multimodality treatment regimen for LAGC has yet to be determined. In aiming to improve outcomes, current trials are examining immunotherapies and targeted therapies based on a growing understanding of the unique molecular characteristics and subtypes of LAGC.
  • 218
  • 01 Sep 2023
Topic Review
Mesenchymal Stem Cell-Derived Extracellular Vesicles for Neurodegenerative Disabilities
Mesenchymal stem cells (MSCs) are a type of versatile adult stem cells present in various organs. These cells give rise to extracellular vesicles (EVs) containing a diverse array of biologically active elements, making them a promising approach for therapeutics and diagnostics. 
  • 1.7K
  • 01 Sep 2023
Topic Review
Coronary No-Reflow after Primary Percutaneous Coronary Intervention
Coronary no-reflow (CNR) is a frequent phenomenon that develops in patients with ST-segment elevation myocardial infarction (STEMI) following reperfusion therapy. CNR is highly dynamic, develops gradually (over hours) and persists for days to weeks after reperfusion. Microvascular obstruction (MVO) developing as a consequence of myocardial ischemia, distal embolization and reperfusion-related injury is the main pathophysiological mechanism of CNR. The frequency of CNR or MVO after primary PCI differs widely depending on the sensitivity of the tools used for diagnosis and timing of examination. Coronary angiography is readily available and most convenient to diagnose CNR but it is highly conservative and underestimates the true frequency of CNR. Cardiac magnetic resonance (CMR) imaging is the most sensitive method to diagnose MVO and CNR that provides information on the presence, localization and extent of MVO. CMR imaging detects intramyocardial hemorrhage and accurately estimates the infarct size. MVO and CNR markedly negate the benefits of reperfusion therapy and contribute to poor clinical outcomes including adverse remodeling of left ventricle, worsening or new congestive heart failure and reduced survival.
  • 576
  • 01 Sep 2023
Topic Review
Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma
Immune checkpoint inhibitor-based therapies represent the current standard of care in the first-line treatment of advanced renal cell carcinoma.
  • 322
  • 01 Sep 2023
Topic Review
Thymic Stromal Lymphopoietin, Its Receptors and Molecular Interactions
Thymic stromal lymphopoietin (TSLP) is a pleiotropic cytokine that has emerged as a critical player in the development and progression of allergy and asthma. It is primarily produced by epithelial cells and functions as a potent immune system activator.
  • 229
  • 01 Sep 2023
  • Page
  • of
  • 1349
Video Production Service